Sharman JP, et al. - Given that a randomized, double-blind, phase III study of idelalisib (IDELA) plus rituximab vs placebo plus rituximab in patients with relapsed chronic lymphocytic leukemia (CLL) was stopped early due to superior effectiveness of the IDELA-plus-rituximab (IDELA/R) arm, researchers reported the long-term effectiveness and safety data for IDELA-treated patients across the primary and extension studies. In patients with relapsed CLL, IDELA improved progression-free survival and overall survival vs rituximab alone. IDELA was effective over the long term and had an expected safety profile. No new adverse events associated with IDELA have been identified with longer exposure.